Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that it has presented new pre-clinical data from its investigational RNAi therapeutic programs ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE